SF1126 for Patients With Relapsed or Refractory Neuroblastoma

Summary

SF1126 is a novel inhibitor of PI3 kinase and mTOR that includes an active moiety (consisting of LY294002) linked to an RGDS tetrapeptide that targets the active agent to integrin expressing tissues. In this first pediatric phase 1 trial of SF1126, dose escalation will follow a 3+3 dose escalation design. Once a recommended phase 2 pediatric dose is identified, an expansion cohort of 10 patients with tumors with MYCN amplification, Mycn expression, or Myc expression will be treated. Funding Source - FDA OOPD

Timeline

Start

2015-07-09

Primary completion

2018-05-22

Completion

2018-05-22

Outcome

Outcome not reported

Stopped (Enrollment): “Low patient accrual”

Drugs

Indications